Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), a pharmaceutical manufacturer headquartered in India, has renewed its Good Manufacturing Practices (GMP) certification from the State Service of Ukraine on Medicines and Drugs Control (SMDC). The certification applies to the company’s Unit II facility in Baddi, Himachal Pradesh.
This certification covers Venus Remedies’ production lines for cephalosporin, non-cephalosporin (carbapenem), and oncology parenteral formulations, including both liquid and lyophilized injections.
Ukraine is a member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S), a global framework that includes 56 regulatory authorities from regions across Europe, Asia, Oceania, and the Americas. This renewal supports Venus Remedies’ existing operations in 32 PIC/S member countries, including markets such as South Africa, Thailand, Malaysia, Saudi Arabia, and Australia.
Venus Remedies has maintained a presence in the Ukrainian pharmaceutical market for over two decades, with 44 product registrations. The market is forecasted to grow at a compound annual growth rate (CAGR) of 3.9%, reaching an estimated value of USD 822.26 million by 2029, driven by increasing demand for generics and oncology treatments.
Ahmedabad Plane Crash